March 13, 2014 — Boston Scientific Corp. received CE marking for the Rebel Platinum Chromium Coronary Stent System, the company's latest generation bare metal stent for the treatment of coronary artery disease (CAD).
The Rebel offers physicians the same stent platform as the Promus Premier drug-eluting stent (DES), but without the everolimus drug. Bare metal stents continue to play an important role in the treatment of coronary artery disease and represent a significant portion of the global stent market.
The Rebel features visibility, low recoil, radial strength and fracture resistance, while improving axial strength and deliverability. Its enhanced low-profile delivery system also features a shorter, more visible tip, a dual-layer balloon and a bi-segment inner lumen catheter designed to facilitate precise stent delivery across challenging lesions.
The Rebel Stent System is offered in a matrix of 48 sizes, ranging in diameter from 2.25 to 4.5 mm and lengths of 8 to 32 mm on a monorail platform.
Data from the OMEGA clinical trial evaluating the Platinum Chromium Bare Metal Stent System were presented in February by John C. Wang, M.D., Medstar Union Memorial Hospital, Baltimore, Md. at the Cardiovascular Research Technologies conference, Washington, D.C. OMEGA is a single arm, multi-center trial in the United States and Europe. OMEGA trial data are expected to support a U.S. Food and Drug Administration (FDA) regulatory submission.
In the United States, the Rebel Stent System is an investigational device and not available for sale.
For more information: www.bostonscientific.com